0000899243-20-028422.txt : 20201015
0000899243-20-028422.hdr.sgml : 20201015
20201015201443
ACCESSION NUMBER: 0000899243-20-028422
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200826
FILED AS OF DATE: 20201015
DATE AS OF CHANGE: 20201015
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haddock Jason
CENTRAL INDEX KEY: 0001680628
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201242521
MAIL ADDRESS:
STREET 1: C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
BUSINESS PHONE: 857-400-4222
MAIL ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-26
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001680628
Haddock Jason
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE
MA
02140
1
0
0
0
Stock Option (Right to Buy)
19.47
2020-08-26
4
A
0
31981
0.00
A
2030-08-25
Common Stock
31981
31981
D
Stock Option (Right to Buy)
15.00
2020-10-13
4
A
0
10000
0.00
A
2030-10-12
Common Stock
10000
10000
D
On October 2, 2020, the Issuer completed a 1-for-7.187 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.
This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
25% of this option shall vest and become exercisable on August 26, 2021, with the remainder vesting in 12 equal quarterly installments thereafter.
This option shall vest in full upon the earlier to occur of (i) October 13, 2021, and (ii) the next annual meeting of the Issuer's stockholders.
/s/ Yalonda Howze by Power of Attorney for Jason Haddock
2020-10-15